A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of JNJ-67953964 in Subjects With Major Depressive Disorder
Phase of Trial: Phase II
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs JNJ-67953964 (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Janssen Research & Development; Janssen-Cilag
- 17 Oct 2019 Planned primary completion date changed from 11 Nov 2019 to 13 May 2020.
- 08 Mar 2019 Planned number of patients changed from 142 to 172.
- 08 Feb 2019 Planned End Date changed from 19 Nov 2019 to 13 May 2020.